Condition: Seminoma · Stage II · Sponsor: Centre Leon Berard
Phase II, multicenter, prospective, randomized, non-comparative, de-escalation study. Patients with stage IIa/IIb \< 3 cm seminoma histologically proved after orchiectomy will be included in the study and will receive 1 cycle of Etoposide Cisplatine (EP) chemotherapy. Patients with negative week-3 PET-scan after the EP cycle, will be randomized (1:1 ratio, stratification according to the disease stage (stage IIa versus IIb seminoma)) to receive either radiotherapy (RT) boost on lymph nodes or 1 cycle of carboplatin AUC7 chemotherapy. Patients with positive week-3 PET-scan will received 3 additional cycles of EP chemotherapy. In parallel, eligible patients scheduled to receive standard lombo-aortic RT will be registered in an observational cohort.
This description comes directly from the study's public registry record.
Ellen BLANC · +33 4 78 78 29 67 · ellen.blanc@lyon.unicancer.fr
Aude FLECHON, Dr · + 33 4 78 78 26 43 · aude.flechon@lyon.unicancer.fr
Always discuss trial participation with your own doctor first.
| CHU Besançon | Besançon, France | Not Yet Recruiting |
| CHU Bordeaux | Bordeaux, France | Recruiting |
| Centre François Baclesse | Caen, France | Recruiting |
| Centre Jean Perrin | Clermont-Ferrand, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| CHU de Limoges | Limoges, France | Recruiting |
| Centre Leon Bérard | Lyon, France | Recruiting |
| Institut Paoli Calmettes | Marseille, France | Recruiting |
| Centre Antoine Lacassagne | Nice, France | Recruiting |
| Hôpital Saint Louis | Paris, France | Not Yet Recruiting |
| ICO René Gauducheau | Saint-Herblain, France | Recruiting |
| Hôpital Foch | Suresnes, France | Not Yet Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05529251